Fickweiler, Ward <br/><br/>
Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial.  [electronic resource] 

 -  Investigative ophthalmology & visual science  11 2016 
 - 6234-6241 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1552-5783 
<br/><br/><label>Standard No.: </label>10.1167/iovs.16-20157  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Bevacizumab--administration & dosage<br/>Biomarkers--blood<br/>Diabetic Retinopathy--blood<br/>Dose-Response Relationship, Drug<br/>Eye Proteins--blood<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Intravitreal Injections<br/>Macular Edema--blood<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>RNA, Messenger--blood<br/>Ranibizumab--administration & dosage<br/>Retina--pathology<br/>Tomography, Optical Coherence<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity